Gene Therapy Trial at the Retina Foundation of the Southwest featured in The Dallas Morning News
Mason Two Crow, 22, first came to the Retina Foundation in 2003 with a diagnosis of X-linked retinoschisis, a rare genetic condition affecting the retina. Two years ago he came in for a follow-up appointment where he learned that he had the opportunity to be one of the very first to ever be enrolled in a gene therapy trial for his rare eye disease. Mason gives credit to the research scientists at the Retina Foundation for gifting him with the hope that a cure for X-linked retinoschisis may be on the horizon. Click here to read more of Mason’s incredible story on www.dallasnews.com.
Related Articles
Age-Related Macular Degeneration Happenings at the Foundation Recently@Retina Newsletter December 2023 iPad Games Could Be the Future Lazy Eye Treatment Retina Foundation Lands Rising Star in AMD Research for Stem Cell Breakthroughs The Rosewood Foundation And Retina Foundation Of The Southwest Partner Up Again For “Keeping An Eye On Innovation” Series